Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Tschavgov, S.
IL-23 and IL-17 inhibitors in the therapy of psoriasis
Humanmedizin; [ Diplomarbeit ] Medizinische Universität Graz; 2022. pp. 131
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Binder Barbara
- Weger Wolfgang
- Altmetrics:
- Abstract:
- Abstract Background: As psoriasis is a chronic immune-mediated disease and the quality of life of patients can be massively affected by the disease, effective therapy is required, both in terms of a rapid and efficient response within the first 12-16 weeks and in terms of long-term management of the disease. Objective: The aim of this work is to compare the efficacy of IL-17 and IL-23 antagonists in terms of their PASI75/90/100 response both in induction therapy and in long-term therapy. Likewise, it will be investigated whether there are differences in treatment response at difficult-to-treat sites (e.g., nails, scalp, etc.) or in the safety profile between the two classes of treatment agents. Another aspect of the present work is to show whether it is possible to formulate a therapy recommendation for the individual psoriasis patient. Methods: A thorough literature review was performed to collect the relevant data for the time period between 1997 and 2022. Results: All biologicals have shown good efficacy in patients suffering from psoriasis and are thus able to improve the lesions and the quality of life of those affected. This is especially true for secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab and risankizumab. Overall, these new drugs have a favorable side effect profile, although it can be said that the IL-23 inhibitors have shown a slightly more favorable side effect profile, as there has been an increased incidence of candida infections, IBD, and injection side reaction with the IL-17 inhibitors. Regarding special locations and itching, it has been found that unfortunately there are not enough studies yet and they are too different to detect differences between the groups. However, there has been improvement with both IL-17 and IL-23 inhibitors. Conclusion: IL-17, IL-23and IL12/23 inhibitors have reached new standards in the therapy of this life-long condition and can thus improve the lives of many sufferers. However, more information is needed to fully understand the differences between these drugs.